Real-world comparative effectiveness of rivaroxaban versus heparin and phenprocoumon for the treatment and secondary prevention of venous thromboembolism (RECENT)

Study identification

• EU PAS number:
  EUPAS36102
• Study ID:
  46933
• Official title and acronym:
  Real-world comparative effectiveness of rivaroxaban versus heparin and phenprocoumon for the treatment and secondary prevention of venous thromboembolism (RECENT)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  The primary objective of this study is: - To assess the risk of recurrent venous thromboembolic (VTE) events in VTE patients treated with rivaroxaban compared to patients treated with low-molecular-weight heparin (LMWH) and Phenprocoumon The secondary objective of this study is: - To assess the risk of fatal bleeding in VTE patients treated with rivaroxaban compared to patients treated with LMWH and Phenprocoumon
• Study status:
  Finalised

Research institutions and networks

Institutions

Bayer AG

Study timelines

Date when funding contract was signed

Planned: 01/06/2020

Actual: 01/06/2020

Study start date

Planned: 31/07/2020

Actual: 08/07/2020

Date of final study report

Planned: 23/08/2021

Actual: 10/01/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer AG

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable